Department of Neurology, Division of Neurocritical Care, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Crit Care Med. 2012 May;40(5):1601-8. doi: 10.1097/CCM.0b013e318241e380.
Elevated intracranial pressure is one of the proposed mechanisms leading to poor outcomes in patients with intraventricular hemorrhage. We sought to characterize the occurrence and significance of intracranial hypertension in severe intraventricular hemorrhage requiring extraventricular drainage.
Prospective analysis from two randomized, multicenter, clinical trials.
Intensive care units of 23 academic hospitals.
One hundred patients with obstructive intraventricular hemorrhage and intracerebral hemorrhage volume <30 mL requiring emergency extraventricular drainage from two randomized multicenter studies comparing intraventricular recombinant tissue plasminogen activator (n=78) to placebo (n=22).
Intracranial pressure was recorded every 4 hrs in all patients and before and after a 1-hr extraventricular drainage closure period after injection. Intracranial pressure readings were analyzed at predefined thresholds and compared between treatment groups, before and after injection of study agent, and before and after opening of third and fourth ventricles on computed tomography. Impact on 30-day outcomes was assessed.
Initial intracranial pressure ranged from -2 to 60 mm Hg (median; interquartile range, 11;10). Of 2576 intracranial pressure readings, 91.5% (2359) were ≤20 mm Hg, 1.6% were >30, 0.5% were >40, and 0.2% were >50 mm Hg. In a multivariate analysis, threshold events>20 mm Hg and >30 mm Hg were more frequent in placebo vs. recombinant tissue plasminogen activator-treated groups (p=.03 and p=.08, respectively). Intracranial pressure elevation>20 mm Hg occurred during a required 1-hr extraventricular drainage closure interval in 207 of 868 (23.8%) injections of study agent, although early reopening of the extraventricular drainage only occurred in 7.9%. After radiographic opening of the lower ventricular system, intracranial pressure events>20 mm Hg remained significantly associated with initial intraventricular hemorrhage volume (p=.002) and extraventricular drainage placement ipsilateral to the largest intraventricular hemorrhage volume (p=.001), but not with thrombolytic treatment (p=.05) or intracerebral hemorrhage volume (p=.14). Ventriculoperitoneal shunts were required in 13.6% of placebo and 6.4% of recombinant tissue plasminogen activator-treated patients (p=.37). Percentage of intracranial pressure readings per patient>30 mm Hg and initial intracerebral hemorrhage and intraventricular hemorrhage volumes were independent predictors of 30-day mortality after adjustment for other outcome predictors (p=.003, p=.03, and p<.001, respectively). Independent predictors of poor modified Rankin Scale score at 30 days were percent of intracranial pressure events>30 mm Hg per patient (p=.01; but not >20 mm Hg), both intracerebral hemorrhage and intraventricular hemorrhage volume, and pulse pressure.
Intracranial pressure is not frequently elevated during monitoring and drainage with an extraventricular drainage in patients with severe intraventricular hemorrhage, although intracranial pressure >30 mm Hg predicts higher short-term mortality. Thrombolytic therapy may reduce the frequency of high intracranial pressure events. Intracranial pressure elevation appears to be significantly correlated with extraventricular drainage placement in the ventricle with greatest clot volume.
颅内压升高是导致脑室出血患者预后不良的一个假说机制。我们旨在描述需要行脑室外引流(EVD)的严重脑室出血患者中颅内高压的发生和意义。
来自两项随机、多中心临床试验的前瞻性分析。
23 家学术医院的重症监护病房。
两项比较脑室注射重组组织型纤溶酶原激活剂(rt-PA)(n=78)与安慰剂(n=22)治疗梗阻性脑室出血和<30ml 脑内血肿患者的多中心随机研究中需要紧急 EVD 的 100 例患者。
所有患者每隔 4 小时记录一次颅内压,在注射前后的 1 小时 EVD 关闭期间记录颅内压。在预定阈值下分析颅内压读数,并在治疗组之间、研究药物注射前后、CT 下第三和第四脑室开放前后进行比较。评估对 30 天结局的影响。
初始颅内压范围为-2 至 60mmHg(中位数;四分位距,11;10)。在 2576 次颅内压读数中,91.5%(2359 次)<20mmHg,1.6%>30mmHg,0.5%>40mmHg,0.2%>50mmHg。多变量分析显示,安慰剂组比重组组织型纤溶酶原激活剂治疗组阈值事件>20mmHg 和>30mmHg 的更频繁(p=.03 和 p=.08)。在研究药物的 868 次注射中有 207 次(23.8%)在需要的 1 小时 EVD 关闭期间发生颅内压升高>20mmHg,尽管仅在 7.9%的情况下早期重新开放 EVD。在下脑室系统放射状开放后,颅内压升高>20mmHg 仍与初始脑室出血体积(p=.002)和 EVD 放置在最大脑室出血同侧(p=.001)显著相关,但与溶栓治疗(p=.05)或脑内血肿体积(p=.14)无关。安慰剂组 13.6%和重组组织型纤溶酶原激活剂治疗组 6.4%的患者需要行脑室-腹腔分流术(p=.37)。每位患者颅内压读数>30mmHg 的比例和初始脑内血肿和脑室出血体积是调整其他结局预测因素后 30 天死亡率的独立预测因素(p=.003、p=.03 和 p<.001)。调整其他预后预测因素后,30 天改良 Rankin 量表评分不良的独立预测因素为每位患者颅内压>30mmHg 的事件比例(p=.01;但不是>20mmHg)、脑内血肿和脑室出血体积以及脉搏压。
在严重脑室出血患者中,尽管颅内压>30mmHg 可预测短期死亡率较高,但在 EVD 监测和引流期间颅内压并不经常升高。溶栓治疗可能会降低颅内压升高事件的频率。颅内压升高与 EVD 放置在具有最大血凝块体积的心室中显著相关。